Shashank Jain, MD
Interventional Cardiology · Mesa, AZNPI 1588824007
Payments from drug & device makers
Across 197 payments — averaging $87.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- Medtronic$4K
- Boston Scientific$2K
- Edwards Lifesciences$2K
- Abiomed$1K
- Inari Medical, Inc.$461
- plus $2K from 22 others
What the payments were for
- Travel & lodging$8,92652%
- Food & beverage$8,34348%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 42 | $5,382 |
| Medtronic(2 entities) | 55 | $3,689 |
| Boston Scientific | 15 | $2,349 |
| Edwards Lifesciences | 20 | $2,064 |
| Abiomed | 11 | $1,264 |
| Inari Medical, Inc. | 6 | $461 |
| Atricure, Inc. | 4 | $325 |
| Philips North America LLC | 7 | $286 |
| Biosense Webster, Inc. | 2 | $277 |
| Kestra Medical Technology Services, Inc. | 3 | $272 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $217 |
| Johnson & Johnson | 2 | $172 |
| Stryker | 4 | $92 |
| Novartis | 3 | $60 |
| Davol Inc. | 1 | $53 |
| AstraZeneca | 2 | $35 |
| Bayer | 2 | $34 |
| Boehringer Ingelheim | 1 | $28 |
| Pfizer | 2 | $28 |
| Imperative Care, Inc | 1 | $26 |
| ZOLL Respicardia, Inc. | 1 | $26 |
| Amgen | 1 | $23 |
| Cvrx, Inc. | 1 | $22 |
| Impulse Dynamics (USA) Inc. | 1 | $19 |
| Cardiovascular Systems Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Teleflex LLC | 1 | $18 |
| Chiesi USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$1,478
- PASCAL$1,296
- Impella$1,248
- Ensite Cardiac Mapping System$1,166
- TRICLIP$1,024
- ENSITE PRECISION$985
- AVEIR$945
- VersaCross Access Solution$753
- FLOWTRIEVER CATHETER, S$363
- CT THROMBECTOMY SYSTEM KIT$363
- SAPIEN 3 Ultra RESILIA$351
- AZURE XT DR MRI SURESCAN$329
- SelectSecure$307
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$285
- Carto 3$277
- ENSITE$244
- RESOLUTE ONYX$230
- CoreValve Evolut$157
- XARELTO$150
- Assure WCD$148
How this compares
$17,269 in reported general payments places this provider in the 60th percentile of 223 interventional cardiology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 244 | $223,869 |
| EntrestoSacubitril/Valsartan | 89 | $71,899 |
| FarxigaDapagliflozin Propanediol | 78 | $51,416 |
| BrilintaTicagrelor | 49 | $28,806 |
| XareltoRivaroxaban | 32 | $24,293 |
| Repatha SureclickEvolocumab | 11 | $8,772 |
| ClopidogrelClopidogrel Bisulfate | 236 | $1,928 |
| Atorvastatin Calcium | 247 | $1,689 |
| Rosuvastatin Calcium | 137 | $1,384 |
| Metoprolol Succinate | 151 | $1,315 |
| Metoprolol Tartrate | 186 | $917 |
| Carvedilol | 134 | $866 |
| Furosemide | 180 | $786 |
| Losartan Potassium | 73 | $586 |
| Amiodarone Hcl | 37 | $474 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $28 | $223,869244 claims |
| AstraZenecaFarxiga, Brilinta | $35 | $80,222127 claims |
| NovartisEntresto | $60 | $71,89989 claims |
| Johnson & JohnsonXarelto | $172 | $24,29332 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 223 interventional cardiology providers in Arizona.
Other interventional cardiology in Mesa
- Nachiket PatelMesa$271K
- Jaskamal KahlonMesa$202K
- Alphonse AmbrosiaMesa$180K
- I-Hui ChiangMesa$165K
- Faraj KargoliMesa$115K
- Satya Prakash AtmakuriMesa$43K
- Robert CandipanMesa$33K
- Paul SorajjaPhoenix$8.8M
- Thomas WaggonerTucson$4.1M
- Hursh NaikAvondale$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.